De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bionime Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Bionime is gedaald met een gemiddeld jaarlijks percentage van -26.1%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 11.2%. De inkomsten zijn daalde met een gemiddeld percentage van 1.4% per jaar.

Belangrijke informatie

-26.1%

Groei van de winst

-27.2%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	11.5%
Inkomstengroei	-1.4%
Rendement op eigen vermogen	-2.1%
Nettomarge	-2.1%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Mar 23

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Mar 05

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Feb 15

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Feb 01

How Has Bionime (TPE:4737) Allocated Its Capital?

Jan 19

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

Jan 06

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Dec 22

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Dec 09

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Nov 24

Opbrengsten en kosten

Hoe Bionime geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TWSE:4737 Opbrengsten, kosten en inkomsten (TWD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	1,858	-40	559	303
31 Mar 24	1,809	7	507	247
31 Dec 23	1,756	6	487	242
30 Sep 23	1,863	22	538	218
30 Jun 23	2,002	43	594	211
31 Mar 23	2,150	72	649	207
31 Dec 22	2,211	91	671	202
30 Sep 22	2,091	95	588	194
30 Jun 22	2,023	115	567	189
31 Mar 22	1,862	89	525	185
31 Dec 21	1,850	87	520	188
30 Sep 21	1,879	101	546	188
30 Jun 21	1,832	111	534	209
31 Mar 21	1,779	83	532	231
31 Dec 20	1,669	62	480	248
30 Sep 20	1,913	73	531	261
30 Jun 20	1,951	38	532	266
31 Mar 20	2,162	91	558	276
31 Dec 19	2,173	106	537	255
30 Sep 19	2,043	112	468	254
30 Jun 19	2,113	132	473	233
31 Mar 19	1,986	121	452	205
31 Dec 18	2,007	128	475	201
30 Sep 18	1,962	114	475	190
30 Jun 18	1,842	135	438	171
31 Mar 18	1,821	137	396	165
31 Dec 17	1,820	150	387	160
30 Sep 17	1,771	174	369	140
30 Jun 17	1,780	181	365	146
31 Mar 17	1,791	192	378	145
31 Dec 16	1,740	179	372	140
30 Sep 16	1,654	143	375	137
30 Jun 16	1,637	119	386	133
31 Mar 16	1,571	91	389	124
31 Dec 15	1,610	99	394	118
30 Sep 15	1,634	101	386	109
30 Jun 15	1,591	82	353	97
31 Mar 15	1,571	72	351	93
31 Dec 14	1,525	54	353	92
30 Sep 14	1,446	22	335	103
30 Jun 14	1,459	43	353	106
31 Mar 14	1,536	72	376	102
31 Dec 13	1,561	90	382	101

Kwaliteitswinsten: 4737 is momenteel verliesgevend.

Groeiende winstmarge: 4737 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 4737 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 26.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 4737 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 4737 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 3.5% ).

Rendement op eigen vermogen

Hoge ROE: 4737 heeft een negatief Return on Equity ( -2.09% ), omdat het momenteel verliesgevend is.

Bionime Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$0.10 (vs NT$1.50 in FY 2022)

Second quarter 2023 earnings released: EPS: NT$0.17 (vs NT$0.65 in 2Q 2022)

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q2, 2024 Results on Aug 08, 2024

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Upcoming dividend of NT$2.00 per share

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to NT$2.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$0.10 (vs NT$1.50 in FY 2022)

Bionime Corporation, Annual General Meeting, Jun 28, 2024

New minor risk - Earnings quality

Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License

Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer

Second quarter 2023 earnings released: EPS: NT$0.17 (vs NT$0.65 in 2Q 2022)

Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee

Upcoming dividend of NT$2.10 per share at 2.7% yield

Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to NT$85.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System

Second quarter 2022 earnings released: EPS: NT$0.65 (vs NT$0.22 in 2Q 2021)

Less than half of directors are independent

Upcoming dividend of NT$2.00 per share

Bionime Corporation Announces Members of the First Order Audit Committee of the Company

Less than half of directors are independent

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.68 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.26 loss in 2Q 2020)

Upcoming dividend of NT$2.06 per share

First quarter 2021 earnings released: EPS NT$0.20 (vs NT$0.14 loss in 1Q 2020)

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Full year 2020 earnings released: EPS NT$1.06 (vs NT$1.85 in FY 2019)

Bionime Corporation Announces Dividend for the Year 2020

Bionime Corporation, Annual General Meeting, Jun 24, 2021

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Investor sentiment improved over the past week

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

New 90-day low: NT$62.30

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Bionime Corporation Announces Change to the Principal Accounting Officer of the Company

New 90-day low: NT$64.50

How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$68.20

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Third quarter 2020 earnings released: EPS NT$0.68

First half earnings released

Upcoming Dividend of NT$1.99 Per Share

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden